Chronic GVHD After Allo-SCT Would Be Necessary For Better Outcome Of Allogenic Stemcell Transplantation (Allo-SCT) For Chemorefractory Non-Hodgkin's Lymphomas -A Single Institute Retrospective Study  by Nakano, N. et al.
Poster Session I S239received prior chemotherapy and 24% had received a prior stem cell
transplant. 48% of patients had not yet relapsed and 33% were cur-
rently symptomatic. Physicians were predominantly hematologists
(93%) who have been in practice on average for 12.2 years. 46% of
physicians reported being in a practice that includes stem cell trans-
plantation. For all participants, remission length was the major pos-
itive influence on choice (p\0.001), and toxicity of ALLO was the
major negative influence (p\0.001). Cost was a significant negative
influence on choice for physicians (p5 0.001), but not for patients.
By post-estimation analysis, patients were most likely to choose
AUTO (69%) and less likely to choose RIT (14%), CT (11%),
and ALLO (7%). The distribution for physicians was similar.
Conclusions: Patients with relapsed follicular lymphoma are able to
consider the advantages and disadvantages of various treatment op-
tions, and most are willing to trade off toxicity, hospitalization,
and cost associated with autologous transplantation in order to ben-
efit from increased remission length.218
CHRONIC GVHD AFTER ALLO-SCT WOULD BE NECESSARY FOR BETTER
OUTCOME OF ALLOGENIC STEMCELL TRANSPLANTATION (ALLO-SCT)
FOR CHEMOREFRACTORY NON-HODGKIN’S LYMPHOMAS -A SINGLE IN-
STITUTE RETROSPECTIVE STUDY
Nakano, N.1,2, Takatsuka, Y.1, Tokunaga, M.1, Takeuchi, S.1,
Kubota, A.1, Tokunaga, M.1, Utsunomiya, A.1 1 Imamura Bun-in Hospi-
tal, Kagoshima, Japan; 2Toranomon Hospital, Tokyo, Japan
Aims:The aims of this study are to identify the feasibility and clinical
characteristics of the patients undergone Allo-SCT for chemo-re-
fractory NHLs.
Design and methods: There were 55 NHL patients who had been
undergone allo-SCT in our institute from August 2001 to March
2009 consecutively. Thirty-seven patients out of 55 were adult T-
cell leukemia/lymphoma (ATLL) patients, and we analyzed about
rest of 18 patents. Study endpoints were 3 years overall survival
(OS), disease free survival (DFS) and these related factors.
Results: Median age was 37.5 yrs (19-63). Thirteen patients were
male and 5 female. Diagnosis included FL (n5 4), PTCL-u
(n5 3), MNKL (n5 3), BL (n5 2), DLBCL (n5 2), ALCL
(n5 1), T-LBL (n5 1), hepatosplenic lymphoma (n5 1), and MF
(n5 1). Median overall survival time and disease free survival time
after SCT were 215.5 days (6-2436) and 73 days (2-2436). Overall
survival rate after SCT was 38.9%. IPI was Low in 2 patients, 8 L-
I, 5 H-I, and 3 High. Low/L-I group showed significantly superior
OS, DFS compare to H-I/High group (54% vs 0%, 56.3% vs 0%).
HCT-CI scoring 0 in 12 patients, five 1, and only one patient scored
over 2. HCT-CI score significantly related to OS after SCT in our
cases. There were 13 sibling donors (included 5HLAhaplo-identical
donors) and 5 unrelated donors (URD) (included 2 cord blood do-
nors) in our cases. Ten patients received myeloablative conditioning
and 8 reduced intensity conditioning (RIC). Disease status at SCT
was CR in 5 patients, 7 PR, and 6 PD. Eleven patients died after
SCT (3 a-GVHD, 2 disease progression, 2 sepsis, 1 TMA, 1 pneu-
monia, 1 invasive aspergirosis, and 1 liver failure). Five patients
died within 100 days after SCT. Six patients have been alive over 3
years (3 yrs OS, DFS: 33.3%, 27.8%). Seven patients were compli-
cated grade 0-1 a-GVHD and 9 grade 2-4. Grade 0-1 group patients
showed significantly superior DFS compare to grade 2-4. Five pa-
tients complained limited c-GVHD and 3 extensive. The patients
group complained with c-GVHD showed better OS and DFS than
asymptomatic group (53.6% vs 12.0%, 58.3% vs 12.5%). Four pa-
tients suffered relapse or progressive disease after SCT. Two out
of these 4 patients showed GVL effect only with reducing immuno-
suppressive therapies.
Conclusion: Allo-SCT would be feasible therapy for chemorefrac-
tory NHLs. Chronic GVHD will be necessary and GVL effect
would be existed in our study.219
PRESENCE OF ABNORMAL PLASMA CELLS IN PERIPHERAL STEM CELL
HARVEST PRODUCTS PREDICT EARLY RELAPSE FOLLOWING AUTOLO-
GOUS STEM CELL TRANSPLANTATION IN PATIENTSWITHMULTIPLEMY-
ELOMA
Bakanay, S.M., Dalva, K., Koksoy, B.E., Civriz, S., Ayyildiz, E.,
Arat, M., Ozcan, M., Ilhan, O., Beksac, M. Ankara University, Ankara,
Turkey
Background: CD38 + 138+ stem cells more than 4.5 x10 5/kg has
been found to shorten overall survival (Kopp, 2009). The EBMT re-
port on the impact of plasma cell cytoreduction in apeheresis prod-
ucts has shown that despite major tumor cell elimination relapse
could not be eliminated(Bourhis, 2007). Flow cytometry has been
claimed to be of lesser specificity than PCR. The multiparametric
flow cytometry has the potential to quantify and distinct normal
plasma cells from abnormal plasma cells. The aim of this prospective
study was to analyze the amount of both normal and abnormal
plasma cells in peripheral stem cell products and correlate with clin-
ical outcome.
Patients: A total of 47 consecutive multiple myeloma patients who
were mobilized between March 2007 and July 2009 were included
in the study. Patients were male/female: 26/21; ISS: I/II/III: 17/
18/11; age: 54 (35 -65). Treatment preceding transplant consisted
of novel agent including protocols (n: 13) or excluding protocols(n:
34). Plasma cell quantification was done using a panel of monoclonal
antibodies by using multiparameter flowcytometry. If any aberrant
expression (such as CD20(loss) CD27(loss) CD28 (gain),
CD33(loss), CD34 (gain), CD81(loss), CD117(gain)) were detected
at diagnosis, the corresponding antibody was also added to the panel.
Results: Abnormal plasma cells were detected in 9 apheresis prod-
ucts from 8 patients. The median plasma cell count (normal plus ab-
normal) was 6.53 (0,19-542) x 105/kg. In the abnormal plasma cell
positive group the median total and abnormal plasma cell counts
were 2.73 (0.19-542) x105/kg and 1.4 (0.07-542) x105/kg, respec-
tively. Twenty five patients had $4.5 x105/kg (high) plasma cells
while 17 patients has\4.5 x105/kg (low) plasma cells.Similar rate
of response (.5 PR) was obtained in 5/7 patients with plasma cell
contamination following transplantation. Amongst 18 patients evalu-
able during post transplant 1 year follow up, 10 of the 12(83%) pa-
tients who had high plasma cell count and 3 of 6 (50%) patients
who had low plasma cell count in their products, either progressed
or relapsed.
Conclusion: High dose therapy with stem cell support may induce
high hematological responses confirmed by reduction inmonoclonal
protein production. Patients who have lower amount of plasma cell
contaminating the apheresis products seem to perform better out-
come during the first year follow up after transplantation.
Table 1.
PostResponse
Pre
Mobilisation
Pre
Transplant
Transplant
month2Relapse
\1 yearAbnormal plasma cell
positive6/7 4/7 5/7 4/7Abnormal plasma cell
negative31/34 27/34 27/32 4/13Total 37/41 31/41 7/39 8/20220
HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR MULTIPLE MYELOMA: WHAT PREDICTS THE OUT-
COME?
Kumar, L., Ganess, P., Gogia, A., Ghosh, I., Hariprasad, R. All India In-
stitute of Medical Sciences, New Delhi, Delhi, India; All India Institute of
Medical Sciences, New Delhi, Delhi, India; All India Institute of Medical
Sciences, New Delhi, Delhi, India; All India Institute of Medical Sciences,
New Delhi, Delhi, India; All India Institute of Medical Sciences, New
Delhi, Delhi, India
We analyzed results of 118 patients (84 males and 34 females) of
multiple myeloma who underwent autologous stem cell
